Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients with Myelofibrosis.

submitted by: mcgheekkm

Dr. Animesh Pardanani, Assistant Professor of Medicine and Consultant in the Division of Hematology at Mayo Clinic in Rochester, MN, Discusses his article, coauthored with Dr. Ayalew Tefferi, on potential complications from withdrawal of ruxolitinib. Available at: http://www.mayoclinicproceedings.com/content/early/recent.